Virax Biolabs Group Limited Ordinary Shares Asset Resilience Ratio
Virax Biolabs Group Limited Ordinary Shares asset resilience ratio. Virax Biolabs Group Limited Ordinary Shares (VRAX) has an Asset Resilience Ratio of 1.47% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Virax Biolabs Group Limited Ordinary Sha defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Virax Biolabs Group Limited Ordinary Shares (2023–2025)
Asset resilience ratio of Virax Biolabs Group Limited Ordinary Shares from 2023 to 2025. This chart shows how Virax Biolabs Group Limited Ordinary Shares's Asset Resilience Ratio has changed over time. Read total liabilities of Virax Biolabs Group Limited Ordinary Sha for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Virax Biolabs Group Limited Ordinary Shares's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Virax Biolabs Group Limited Ordinary Sha asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $94.19K | 1.47% |
| Total Liquid Assets | $94.19K | 1.47% |
Asset Resilience Insights
- Limited Liquidity: Virax Biolabs Group Limited Ordinary Shares maintains only 1.47% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Virax Biolabs Group Limited Ordinary Shares Industry Peers by Asset Resilience Ratio
Compare Virax Biolabs Group Limited Ordinary Shares's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Virax Biolabs Group Limited Ordinary Shares Asset Resilience Ratio by Year (2023–2025)
Virax Biolabs Group Limited Ordinary Shares asset resilience ratio by year from 2023 to 2025. The table below shows the annual Asset Resilience Ratio data for Virax Biolabs Group Limited Ordinary Shares.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 1.47% | $94.19K | $6.43 Million | +0.06pp |
| 2024-03-31 | 1.41% | $77.32K | $5.48 Million | +0.91pp |
| 2023-03-31 | 0.50% | $49.26K | $9.81 Million | -- |
About Virax Biolabs Group Limited Ordinary Shares
Virax Biolabs Group Limited, a biotechnology company, distributes diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of T cell in Vitro Diagnostics. The company offers various in-vitro diagnostics test kits comprising respiratory, pregnancy and fertility, infectious diseases, sti, drugs of abuse, oncology, cardiac, women's health, ot… Read more